Sirna, UMMS, Alnylam, Harvard, Fisher Scientific, Thermo Electron, Qiagen | GenomeWeb

Sirna Sees New Big Pharma Collaboration on Horizon ...

Sirna Therapeutics is expecting to ink another big pharma collaboration over the next 12 months, which could allow the company to expand its product pipeline, according to President and CEO Howard Robin.

Speaking last week during a conference call to discuss Sirna's first-quarter financial results, Robin noted that "we are engaged in discussions with many large pharmaceutical companies at this point, and I do believe in the course of the next year you'll see another deal from Sirna."

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Nature this week: modern European bison analysis, phased diploid genome assembly algorithms, and more.

Actress Jennifer Lopez is working with NBC on a CRISPR-inspired television show, according to the Hollywood Reporter.

Researchers trace the origin of one human papillomavirus lineage to Neanderthals or Denisovans, Vox reports.

The BabySeq project faces lower-than-expected enrollment rates, according to ScienceInsider.